Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul 1;1(4):432-440.
doi: 10.4161/onci.19545.

Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients

Manuarii Manuel  1 , Olivier Tredan, Thomas Bachelot, Gilles Clapisson, Anais Courtier, Gilles Parmentier, Tioka Rabeony, Audrey Grives, Solène Perez, Jean-François Mouret, David Perol, Sylvie Chabaud, Isabelle Ray-Coquard, Intidhar Labidi-Galy, Pierre Heudel, Jean-Yves Pierga, Christophe Caux, Jean-Yves Blay, Nicolas Pasqual, Christine Ménétrier-Caux
Affiliations

Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients

Manuarii Manuel et al. Oncoimmunology. .

Abstract

Lymphopenia (< 1Giga/L) detected before initiation of chemotherapy is a predictive factor for death in metastatic solid tumors. Combinatorial T cell repertoire (TCR) diversity was investigated and tested either alone or in combination with lymphopenia as a prognostic factor at diagnosis for overall survival (OS) in metastatic breast cancer (MBC) patients. The combinatorial TCR diversity was measured by semi quantitative multi-N-plex PCR on blood samples before the initiation of the first line chemotherapy in a development (n = 66) and validation (n = 67) MBC patient cohorts. A prognostic score, combining lymphocyte count and TCR diversity was evaluated. Univariate and multivariate analyses of prognostic factors for OS were performed in both cohorts. Lymphopenia and severe restriction of TCR diversity called "divpenia" (diversity ≤ 33%) were independently associated with shorter OS. Lympho-divpenia combining lymphopenia and severe divpenia accurately identified patients with poor OS in both cohorts (7.6 and 10.6 vs 24.5 and 22.9 mo). In multivariate analysis including other prognostic clinical factors, lympho-divpenia was found to be an independent prognostic factor in the pooled cohort (p = 0.005) along with lack of HER2 and hormonal receptors expression (p = 0.011) and anemia (p = 0.009). Lympho-divpenia is a novel prognostic factor that will be used to improve quality of MBC patients' medical care.

PubMed Disclaimer

Figures

None
Figure 1. Overall survival of patients according to their baseline lymphocyte counts (< 1 Giga/L or ≥ 1Giga/L) for patients enrolled in cohort A (A) and cohort B (B). Comparison of TCR diversity in healthy subjects and patients from cohorts A and B (C). Overall survival according to their baseline TCR diversity (≤ 33% or > 33%) for patients enrolled in cohort A (D) and cohort B (E).
None
Figure 2. Overall survival according to baseline TCR diversity (≤ 33% or > 33%) in cohort A within lymphopenic patients (A) or non lymphopenic patients (B).
None
Figure 3. NDL representation on healthy subjects (n = 26) (A), cohort A (n = 66) (B) and cohort B (n = 67) (C). Overall survival according to their lympho-divpenic status (NDL score 1) in the cohort A (n = 66) (D) and cohort B (n = 62) (E).
None
Figure 4. (A) Overall survival according to their lympho-divpenic status (NDL score 1) on the pooled cohort (n = 123) (B) Overall survival according to the different NDL scores i.e: lympho-divpenia (NDL score 1), lymphopenia alone (NDL score 2), divpenia alone (NDL score 3) and neither lymphopenia nor divpenia (NDL score 4).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Blay JY, Chauvin F, Le Cesne A, Anglaret B, Bouhour D, Lasset C, et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol. 1996;14:636–43. - PubMed
    1. Blay JY, Le Cesne A, Mermet C, Maugard C, Ravaud A, Chevreau C, et al. A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. Blood. 1998;92:405–10. - PubMed
    1. Borg C, Ray-Coquard I, Philip I, Clapisson G, Bendriss-Vermare N, Menetrier-Caux C, et al. CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer. 2004;101:2675–80. doi: 10.1002/cncr.20688. - DOI - PubMed
    1. Ray-Coquard I, Borg C, Bachelot T, Sebban C, Philip I, Clapisson G, et al. ELYPSE study group Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer. 2003;88:181–6. doi: 10.1038/sj.bjc.6600724. - DOI - PMC - PubMed
    1. Ray-Coquard I, Ghesquière H, Bachelot T, Borg C, Biron P, Sebban C, et al. ELYPSE Study Group Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. Br J Cancer. 2001;85:816–22. doi: 10.1054/bjoc.2001.2011. - DOI - PMC - PubMed

Publication types